Claudia Dames

Claudia Dames

Auto-generated profile, based on publicly available information

Claudia Dames

Department of Neurology with Experimental Neurology, Center for Stroke Research Berlin, Charité–Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany (C.D., D.B., A.M.).

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
MEMatthias Endres
Matthias Endres
MMMaria A. Moro
Maria A. Moro
CNChristian H. Nolte
Christian H. Nolte
CDClaudia Dames
Claudia Dames
MBMarion S. Buckwalter
Marion S. Buckwalter
AMAndreas Meisel
Andreas Meisel
Inflammation and immune mechanisms are crucially involved in the pathophysiology of the development, acute damage cascades, and chronic course after ischemic stroke. Atherosclerosis is an inflammatory disease, and, in addition to classical risk factors, maladaptive immune mechanisms lead to an increased risk of stroke. Accordingly, individuals with signs of inflammation or corresponding biomarkers have an increased risk of stroke. Anti-inflammatory drugs, such as IL (interleukin)-1β blockers, methotrexate, or colchicine, represent attractive treatment strategies to prevent vascular events and stroke. Lately, the COVID-19 pandemic shows a clear association between SARS-CoV2 infections and increased risk of cerebrovascular events. Furthermore, mechanisms of both innate and adaptive immune systems influence cerebral damage cascades after ischemic stroke. Neutrophils, monocytes, and microglia, as well as T and B lymphocytes each play complex interdependent roles that synergize to remove dead tissue but also can cause bystander injury to intact brain cells and generate maladaptive chronic inflammation. Chronic systemic inflammation and comorbid infections may unfavorably influence both outcome after stroke and recurrence risk for further stroke. In addition, stroke triggers specific immune depression, which in turn can promote infections. Recent research is now increasingly addressing the question of the extent to which immune mechanisms may influence long-term outcome after stroke and, in particular, cause specific complications such as poststroke dementia or even poststroke depression.

1 May 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
WWWilleke F. Westendorp
Willeke F. Westendorp
CDClaudia Dames
Claudia Dames
PNPaul J. Nederkoorn
Paul J. Nederkoorn
AMAndreas Meisel
Andreas Meisel
Stroke remains one of the main causes of mortality and morbidity worldwide. Immediately after stroke, a neuroinflammatory process starts in the brain, triggering a systemic immunodepression mainly through excessive activation of the autonomous nervous system. Manifestations of immunodepression include lymphopenia but also dysfunctional innate and adaptive immune cells. The resulting impaired antibacterial defenses render patients with stroke susceptible to infections. In addition, other risk factors like stroke severity, dysphagia, impaired consciousness, mechanical ventilation, catheterization, and older age predispose stroke patients for infections. Most common infections are pneumonia and urinary tract infection, both occur in ≈10% of the patients. Especially pneumonia increases unfavorable outcome and mortality in patients with stroke; systemic effects like hypotension, fever, delay in rehabilitation are thought to play a crucial role. Experimental and clinical data suggest that systemic infections enhance autoreactive immune responses against brain antigens and thus negatively affect outcome but convincing evidence is lacking. Prevention of poststroke infections by preventive antibiotic therapy did not improve functional outcome after stroke. Immunomodulatory approaches counteracting immunodepression to prevent stroke-associated pneumonia need to account for neuroinflammation in the ischemic brain and avoid further tissue damage. Experimental studies discovered interesting targets, but these have not yet been investigated in patients with stroke. A better understanding of the pathobiology may help to develop optimized approaches of preventive antibiotic therapy or immunomodulation to effectively prevent stroke-associated pneumonia while improving long-term outcome after stroke. In this review, we aim to characterize epidemiology, risk factors, cause, diagnosis, clinical presentation, and potential treatment of poststroke immunosuppression and associated infections.

7 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KWKatarzyna Winek
Katarzyna Winek
SLSebastian Lobentanzer
Sebastian Lobentanzer
BNBettina Nadorp
Bettina Nadorp
SDSerafima Dubnov
Serafima Dubnov
CDClaudia Dames
Claudia Dames
HSHermona Soreq
Hermona Soreq
Significance: Ischemic stroke triggers peripheral immunosuppression, increasing the susceptibility to poststroke pneumonia that is linked with poor survival. The poststroke brain initiates intensive communication with the immune system, and acetylcholine contributes to these messages; but the responsible molecules are yet unknown. We discovered a “changing of the guards,” where microRNA levels decreased but small transfer RNA fragments increased in poststroke blood. This molecular switch may rebalance acetylcholine signaling in CD14 + monocytes by regulating their gene expression and modulating poststroke immunity. Our observations point to transfer RNA fragments as molecular regulators of poststroke immune responses that may be potential therapeutic targets.

23 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CZCamila Fernández Zapata
Camila Fernández Zapata
GGGinevra Giacomello
Ginevra Giacomello
ESEike J. Spruth
Eike J. Spruth
JMJinte Middeldorp
Jinte Middeldorp
GGGerardina Gallaccio
Gerardina Gallaccio
CBChotima Böttcher
Chotima Böttcher
Myeloid cells are suggested as an important player in Alzheimer´s disease (AD). However, its continuum of phenotypic and functional changes across different body compartments and their use as a biomarker in AD remains elusive. Here, we perform multiple state-of-the-art analyses to phenotypically and metabolically characterize immune cells between peripheral blood (n = 117), cerebrospinal fluid (CSF, n = 117), choroid plexus (CP, n = 13) and brain parenchyma (n = 13). We find that CSF cells increase expression of markers involved in inflammation, phagocytosis, and metabolism. Changes in phenotype of myeloid cells from AD patients are more pronounced in CP and brain parenchyma and upon in vitro stimulation, suggesting that AD-myeloid cells are more vulnerable to environmental changes. Our findings underscore the importance of myeloid cells in AD and the detailed characterization across body compartments may serve as a resource for future studies focusing on the assessment of these cells as biomarkers in AD.

1 August 2018 in Journal of Neuroimmunology
Verified
Journal Article
Open access
CDClaudia Dames
Claudia Dames
KWKatarzyna Winek
Katarzyna Winek
YBYasmin Beckers
Yasmin Beckers
OEOdilo Engel
Odilo Engel
AMAndreas Meisel
Andreas Meisel
CMChristian Meisel
Christian Meisel
Stroke-induced immunodepression is an independent risk factor for stroke-associated pneumonia (SAP). Granulocyte-macrophage colony stimulating factor (GM-CSF) has neuroprotective properties in experimental stroke and been demonstrated to reverse immunodepression in sepsis patients. However, whether GM-CSF restores immune function after stroke preventing SAP and improving outcome is unknown. Here, we demonstrated that GM-CSF treatment improved peripheral and pulmonary leukocyte numbers, peripheral cytokine responses, lowered lung bacterial burden in the early course and improved long-term functional outcome after experimental stroke. These data suggest that GM-CSF is promising for stroke treatment since it not only acts neuroprotective in the ischemic brain but may also protect against detrimental post-stroke infections.

1 June 2021 in Journal of Neuroimmunology
Verified
Journal Article
Open access
SJSandra Jagdmann
Sandra Jagdmann
DBDaniel Berchtold
Daniel Berchtold
BGBirgitt Gutbier
Birgitt Gutbier
MWMartin Witzenrath
Martin Witzenrath
AMAndreas Meisel
Andreas Meisel
CDClaudia Dames
Claudia Dames
Stroke-induced immunosuppression contributes to the development of stroke-associated pneumonia (SAP). Experiments in mice demonstrated that apoptosis of IFN-? producing cells and reduced IFN-? secretion resulted in impaired immune responses and the development of pneumonia after middle cerebral artery occlusion (MCAo). In the present study, we investigated the efficacy of intratracheal IFN-? treatment to prevent SAP and demonstrated that modest benefits on pulmonary cytokine response in IFN-? treated stroke mice did not prevent spontaneously developing infections and even slightly reduced bacterial clearance of aspirated pneumococci. Our results suggest that pulmonary IFN-? treatment is not an effective preventive measure for SAP.